We show that the stimulation of human immunodeficiency virus (HIV) brought about by tumor necrosis factor a and phorbol 12-myristate 13-acetate can be inhibited by adding N-acetyl-L-cysteine (NAC). NAC, which replenishes intracellular glutathione, effectively inhibits the tumor necrosis factor a-or phorbol ester-stimulated replication of HIV in acutely infected cell cultures. NAC also inhibits the cytokineenhanced HIV long terminal repeat-directed expression of 3-galactosidase in in vitro HIV model systems. These results show that intracellular thiol levels influence HIV production. Furthermore, because NAC reverses tumor necrosis factor a toxicity both in cells and in animals and is a well-known drug that can be administered orally without known toxicity in humans, these results suggest that NAC is a possible therapeutic agent in AIDS.
3-galactosidase in in vitro HIV model systems. These results
show that intracellular thiol levels influence HIV production. Furthermore, because NAC reverses tumor necrosis factor a toxicity both in cells and in animals and is a well-known drug that can be administered orally without known toxicity in humans, these results suggest that NAC is a possible therapeutic agent in AIDS.
Droge and colleagues (1) have demonstrated that human immunodeficiency virus (HIV)-infected individuals have lower levels of serum acid-soluble thiols and lower levels of intracellular glutathione (GSH) in peripheral blood mononuclear cells (PBMCs). Crystal and colleagues (2) have confirmed and extended these findings by showing that asymptomatic HIV-seropositive individuals have dramatically reduced GSH levels in lung epithelial lining fluid and in blood plasma. Data presented here relate these findings to the regulation of HIV replication by showing that increased intracellular thiol levels block the stimulation of HIV by phorbol 12-myristate 13-acetate (PMA) and tumor necrosis factor a (TNF-a).
Fauci and colleagues (3) have suggested that TNF-a plays a central role in the progression of AIDS. This is consistent with evidence showing that TNF-a levels are abnormally high in serum samples from AIDS patients. These levels rise as opportunistic infections become frequent in patients with AIDS-related complex and AIDS. Furthermore, TNF-a levels are high in all individuals with Communicable Disease Center (CDC) stage IV AIDS (4, 5) .
TNF-a exerts some of its toxic effects by stimulating production of reactive oxidative intermediates (ROIs) (6, 7) . PMA, which mimics lymphokine activities, also stimulates ROI production (7, 8) . Intracellular GSH protects cells by scavenging ROIs; however, the oxidant-buffering capacity of cellular GSH can be overcome by excessive stimulation with TNF-a (9). Thus, drugs that either replenish intracellular GSH or directly scavenge ROIs protect against the toxic effects of TNF-a and other agents that cause oxidative damage.
N-Acetyl-L-cysteine (NAC), which is used clinically to counteract the effects of oxidative stress induced by acetaminophen overdose (10) , has been shown to scavenge oxidants directly and to increase intracellular GSH (11, 12) . In this report, we show that NAC counteracts the in vitro stimulatory effects of TNF-a or PMA on HIV-directed gene expression and inhibits HIV replication in cell lines and PBMC. Thus, we suggest that NAC may be valuable as a therapeutic agent in treating AIDS.
EXPERIMENTAL METHODS
Derivation of an HIV-lacZ Reporter Cell Line. The pNAZ construct used here contains the HIV long terminal repeat (LTR) fused to the bacterial A-galactosidase (lacZ) gene ( Fig.   1 ), the simian virus 40 promoter fused to the neomycin phosphotransferase gene, and the prokaryotic ampicillin resistance gene. This plasmid was introduced into human embryonic kidney-derived 293S cells by using a calcium phosphate transfection procedure. G418-resistant cells were selected and maintained in G418 at 1 mg/ml (GIBCO). Fluorescence activated cell sorter (FACS)-Gal assays (15) showed a broad distribution of basal expression of HIV- titer plate reader (Flow Laboratories). This MUG assay is specific for bacterial galactosidase because the endogenous mammalian galactosidase is inactive at pH 7.0.
Monitoring HIV Infections. MOLT-4 cells were preincubated 45 min with Polybrene, pelleted, and resuspended in RPMI 1640 medium supplemented with 10% fetal calf serum, L-glutamine at 290 jug/ml, penicillin at 100 units/ml, and streptomycin at 70 ,ug/ml (complete RPMI medium). One million cells per sample were infected with HTLV-IIIB at a nominal multiplicity of infection of 3 for 2 hr. Cells were washed twice to remove free virus and cultured in complete RPMI medium with or without TNF-a (10 ng/ml) and with or without 3'-azido-3'-deoxythymidine (AZT) (0.1 jiM). Because of the instability of NAC in solution, cells were centrifuged and resuspended in fresh medium supplemented with these molecules daily. Cell number and HIV core protein (P24) level determinations were made daily with ELISA (Abbott); P24, therefore, represents the amount of antigen accumulated during each day. For microscopy, cells were fixed by adding HgC12 to a final concentration of 1 mM.
For infection of PBMC, cells were isolated from heparinized blood of HIV-negative individuals by Ficoll-Paque density centrifugation and were stimulated for 3 days in RPMI 1640 medium supplemented with 20% fetal calf serum, Lglutamine at 290 ,ug/ml, penicillin at 100 units/ml, streptomycin at 70 ,g/ml, 5% (vol/vol) purified human interleukin 2 (Pharmacia), and phytohemagglutinin at 2 jig/ml. Either TNF-a or PMA stimulates /3-galactosidase expression directed by the HIV LTR in 293.27.2 cells (Fig. 2) . As Fig. 3 shows, these stimulations are inhibited by NAC, an acetylated form of cysteine that scavenges ROIs and supplies cysteine for GSH synthesis in vivo (11, 12) . A similar antagonism between NAC and TNF-a or PMA occurs in a clone of H9, a CD4+ T-cell line, stably transfected with pNAZ (data summarized in Table 1 (18, 19) . The inhibition of PMA stimulation, in contrast, occurs at lower levels of NAC-e.g., 1 mM NAC inhibits 15%, and complete inhibition occurs above 10 mM; this may be from a differential sensitivity of the TNF-a and PMA signaling pathways to NAC. Alternatively, it may reflect differences in the rate of oxidant generation by the two stimulants.
Synergy Between TNF-a and PMA. At maximum, the stimulation by TNF-a and PMA together is substantially higher than for either of the factors used individually (Fig. 2) . This synergistic activation is effectively blocked by NAC (Fig. 3 ). These findings demonstrate (i) that the mechanism ultimately responsible for viral stimulation is not saturated by either TNF-a or PMA acting alone; (ii) that TNF-a and PMA stimulate via at least partially independent pathways; and (iii) that NAC inhibits the independent segments of each of these pathways (because the two pathways are differentially sensitive to NAG).
The DNA-binding protein complex NF-KB plays a major role in regulating HIV transcription (16, 20) . Furthermore, NF-KB has been shown to be an important factor in the stimulation of HIV by TNF-a and PMA. The NAC inhibition of this stimulation is consistent with the idea that intracellular thiol levels influence the regulation of genes whose expression is modulated by NF-KB or other transcription factors.
NAC Inhibits TNF-a and PMA Stimulation of HIV Replication in T Cells. We examined the influence of NAC on viral replication during acute HIV infection in a transformed CD4' T cell line (MOLT-4) and in phytohemagglutinin-stimulated PBMC from HIV-negative subjects. In both cases, NAC blocked the stimulation of HIV replication by TNF-a and PMA and reduced the basal replication of the virus.
TNF-a stimulation increases the production of infectious virions and the HIV core protein (P24) found in the supernatant of MOLT-4 cultures acutely infected with HIV. NAC blocks this stimulation (Fig. 4) at doses similar to those that block HIV-directed /3-galactosidase expression in 293.27.2 cells. Because NAC also reduces HIV replication in MOLT-4 cells infected in the absence of exogenous TNF-a (Fig. 4) , factors responsible for the basal level of viral replication also appear to be influenced by the intracellular thiol levels of the MOLT-4 cells.
These conclusions are substantiated by examination of the formation of syncytia (giant cells) in HIV-infected MOLT-4 cells (Fig. 5) . This classical marker of HIV infection is due to the fusion of infected cells via the viral envelope glycoprotein gp120. TNF-a substantially increases syncytia formation, and, as Fig. 5 shows, inclusion of 30 mM NAC with the TNF-a completely inhibits syncytia formation. Furthermore, as with P24 production, NAC blocks the basal formation of syncytia in the absence of TNF-a (data not shown).
NAC also complements the antiviral activity of AZT, a reverse transcriptase inhibitor used widely to combat HIV infection in AIDS patients. At optimal levels, AZT blocks HIV replication in MOLT4 cells, even with TNF-a (data not shown); however, at suboptimal AZT levels, TNF-a readily stimulates HIV replication, and NAC blocks this stimulation (Fig. 4) . These findings suggest that elevated serum levels of TNF-a in AIDS patients may counter the therapeutic effectiveness of AZT. Thus, raising depleted GSH levels in AIDS patients (e.g., with NAG) may provide an effective adjunct to AZT therapy.
NAC Inhibits HIV Replication in PBMC. PMA or PMA plus TNF-a are good stimulators of viral production in PBMC (isolated from HIV-negative individuals, activated with phytohemagglutinin, and then infected with HTLV-IIIB). Very low concentrations ofNAC (<3 mM) completely inhibit these stimulations (Fig. 6) . Furthermore, higher concentrations of NAC reduce P24 production in both stimulated and unstimulated cultures-i.e., in cultures infected with the virus in the absence of TNF-a or PMA. Because PMA mimics interleukin-mediated activation of T cells and such stimulation is thought to be responsible for evolution of HIV infection from latency to the symptomatic stages of AIDS, these findings with PBMC suggest that NAC may be broadly effective in maintaining latency or in preventing further progression of disease in a symptomatic individual.
Specificity of the Physiological Effects of NAC. Stimulations by TNF-a and PMA that induce HIV replication have been shown to induce oxidative stress (6) (7) (8) . We have shown here that HIV stimulation by these agents is strongly inhibited by NAC, a thiol-containing antioxidant that replenishes GSH, the major physiologic antioxidant in cells. Thus, NAC can be thought of as blocking HIV replication by a mechanism that serves generally to block the effects of oxidative stress. NAC has pleiotropic effects, however, which complicate the evaluation of its specificity in inhibiting HIV expression. As Table 1 shows, the highest concentration of NAC used in our experiments partially inhibited the growth of some of the transformed cell lines. This inhibition is completely reversed upon removal of NAC and does not cause cell death, as viability is always the same as control cultures (>95%; data not shown). Similarly, culturing HIV-infected MOLT-4 cells with 30 mM NAC significantly reduces P24 production and abolishes syncytia formation before the effects of NAC on growth become detectable. Lower concentrations of NAC (e.g., 10 mM) do not affect growth in any of the cultures but still inhibit HIV (albeit less effectively in some cases). Thus, in these models, NAC is specific in the sense that it affects HIV expression more strongly than it affects cell activation and growth.
The specificity of NAC is unequivocal in PBMC. The growth of activated PBMC is unaffected by 30 mM NAC, a concentration far above that which effectively blocks the PMA-stimulated replication of HIV. Thus, in this most physiological comparison, NAC inhibits HIV replication without hampering growth of HIV-infected cells. DISCUSSION TNF-a, which stimulates HIV replication, is also known as cachectin, a molecule at least partially responsible for cachexia or wasting, a condition characterized by anorexia, loss of muscle strength, and dramatic weight loss (22) . shown to induce cachexia in mice (23) similar to that seen in the terminal stages of AIDS (24) . High TNF-a levels are frequently found in AIDS patients, although the relationship between the elevated TNF-a levels and weight loss is unclear (4, 5) . In any event, increases in TNF-a levels (4) and decreases in GSH levels (1) clearly correlate with the progression of AIDS.
We suspect that these changes are tightly coupled. That is, the declining GSH levels in AIDS patients may contribute to the increasing TNF-a levels and vice versa because a decline in intracellular GSH increases sensitivity to TNF-a (9), and TNF-a decreases intracellular GSH. Furthermore, because TNF-a production is stimulated by bacterial and parasitic infections, this positive feedback loop between TNF-a and GSH may explain the rapid progression of the disease once opportunistic infections begin.
The decreased GSH levels in asymptomatic patients may explain another well-known aspect of the progression of AIDS. Because the lungs are highly sensitive to oxidative stress (25) , the frequent and early appearance of lung disorders in AIDS (26-28) could be due to GSH deficits (2) , which reduce protection against oxidants and thereby increase the vulnerability of the lungs. Thus, whether TNF-a plays a primary role in stimulating viral production or merely contributes to AIDS pathology by exacerbating "wasting," there is good reason to attempt to counter TNF-a toxicity in HIV-infected individuals.
Thiol Therapy for AIDS. NAC may provide a safe and effective defense against detrimental depletions of thiol stores and increases in TNF-a levels. This cysteine derivative has been orally administered for nearly 20 yr in the treatment of pulmonary disorders. Its pharmacokinetics and safety are well documented (see, e.g., refs. 12 and 29-31), and it has been shown to completely block acute TNF-a toxicity in vivo in rats (9) . Furthermore, NAC is routinely used in humans to overcome the otherwise lethal oxidative stress caused by acetaminophen overdose by increasing depleted GSH levels (10, 12) .
Treatment of HIV-infected individuals with NAC may serve both to restore lowered thiol levels to counter the TNF-a-GSH spiral, and, as shown here, to inhibit viral replication stimulated by TNF-a and other cytokines. Such treatment could be valuable for maintaining latency in asymptomatic patients, perhaps in conjunction with more aggressive anti-infectious agent chemotherapies that use pentamidine, AZT, and dideoxyinosine.
Thiols other than NAC have also been shown to strongly inhibit HIV. The cysteine analogue penicillamine completely inhibits HIV replication in vitro (32) (33) (34) . In addition, 2,3-dimercapto-1-propanol inhibits HIV production through inhibition of the HIV transactivating protein, Tat (35) . However, although these drugs show strong antiviral activity, their toxicity to humans precludes long-term in vivo use.
Several chemicals and drugs that deliver cysteine or GSH to deficient cells in vivo (cysteine and GSH pro-drugs) are potentially useful (36) ; however, all have some disadvantages. L-Cysteine administered parenterally or orally is quickly oxidized to cystine and is toxic in animals (36) . GSH itself can be administered as an aerosol but does not enter cells except when degraded (36) . Nonetheless, aerosolized GSH and its esters (which can enter cells) have been proposed recently to specifically correct the observed GSH deficiency in lungs in AIDS patients and may be effective for this purpose (2) .
In summary, we have demonstrated that NAC blocks the TNF-a stimulation of HIV replication in vitro in normal PBMC. In addition, we have shown that NAC blocks viral stimulation by PMA, which mimics the activities of interleukins in leukocyte activation. At a basic level, these findings suggest that ROI production and intracellular thiol levels are important in the regulation of gene expression. Furthermore, at a clinical level, they suggest that NAC may block HIV stimulation in vivo by lymphokines produced during leukocyte activation. The question of how well NAC, alone or in combination with other antiretroviral drugs, can inhibit viral production and decrease wasting in AIDS patients could be resolved by an appropriate clinical trial.
